BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32111730)

  • 1. Novel, genetically induced mouse model that recapitulates the histological morphology and immunosuppressive tumor microenvironment of metastatic peritoneal carcinomatosis.
    Tseng SH; Park ST; Lam B; Tsai YC; Cheng MA; Farmer E; Xing D; Hung CF
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32111730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment.
    Tanizaki Y; Kobayashi A; Toujima S; Shiro M; Mizoguchi M; Mabuchi Y; Yagi S; Minami S; Takikawa O; Ino K
    Cancer Sci; 2014 Aug; 105(8):966-73. PubMed ID: 24826982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo modeling of metastatic human high-grade serous ovarian cancer in mice.
    Kim O; Park EY; Klinkebiel DL; Pack SD; Shin YH; Abdullaev Z; Emerson RE; Coffey DM; Kwon SY; Creighton CJ; Kwon S; Chang EC; Chiang T; Yatsenko AN; Chien J; Cheon DJ; Yang-Hartwich Y; Nakshatri H; Nephew KP; Behringer RR; Fernández FM; Cho CH; Vanderhyden B; Drapkin R; Bast RC; Miller KD; Karpf AR; Kim J
    PLoS Genet; 2020 Jun; 16(6):e1008808. PubMed ID: 32497036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of NEOADJUVANT chemotherapy.
    van Baal JOAM; Lok CAR; Jordanova ES; Horlings H; van Driel WJ; Amant FC; Van de Vijver KK
    Virchows Arch; 2020 Oct; 477(4):535-544. PubMed ID: 32179982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer.
    Lee SJ; Yang H; Kim WR; Lee YS; Lee WS; Kong SJ; Lee HJ; Kim JH; Cheon J; Kang B; Chon HJ; Kim C
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34145029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin‑33 expression in ovarian cancer and its possible suppression of peritoneal carcinomatosis.
    Sekiya A; Suzuki S; Tanaka A; Hattori S; Shimizu Y; Yoshikawa N; Koya Y; Kajiyama H; Kikkawa F
    Int J Oncol; 2019 Sep; 55(3):755-765. PubMed ID: 31322193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.
    Khan AN; Kolomeyevskaya N; Singel KL; Grimm MJ; Moysich KB; Daudi S; Grzankowski KS; Lele S; Ylagan L; Webster GA; Abrams SI; Odunsi K; Segal BH
    Oncotarget; 2015 May; 6(13):11310-26. PubMed ID: 25888637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of the immune microenvironment in ovarian cancer patients.
    Yang L; Wang S; Zhang Q; Pan Y; Lv Y; Chen X; Zuo Y; Hao D
    Mol Omics; 2018 Oct; 14(5):341-351. PubMed ID: 30129640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.
    McCool KW; Freeman ZT; Zhai Y; Wu R; Hu K; Liu CJ; Tomlins SA; Fearon ER; Magnuson B; Kuick R; Cho KR
    Cancer Res; 2020 Feb; 80(4):877-889. PubMed ID: 31806642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Giehl E; Kosaka H; Liu Z; Feist M; Kammula US; Lotze MT; Ma C; Guo ZS; Bartlett DL
    Front Immunol; 2021; 12():610042. PubMed ID: 33679747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
    Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
    Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting carcinoma-associated mesothelial cells with antibody-drug conjugates in ovarian carcinomatosis.
    Pascual-Antón L; Sandoval P; González-Mateo GT; Kopytina V; Tomero-Sanz H; Arriero-País EM; Jiménez-Heffernan JA; Fabre M; Egaña I; Ferrer C; Simón L; González-Cortijo L; Sainz de la Cuesta R; López-Cabrera M
    J Pathol; 2023 Oct; 261(2):238-251. PubMed ID: 37555348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
    Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
    J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Host Mesothelin Expression Increases Ovarian Cancer Metastasis in the Peritoneal Microenvironment.
    Hilliard TS; Kowalski B; Iwamoto K; Agadi EA; Liu Y; Yang J; Asem M; Klymenko Y; Johnson J; Shi Z; Marfowaa G; Yemc MG; Petrasko P; Stack MS
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Genomic Sequencing Reveals Novel
    Jung YY; Woo HY; Kim HS
    Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The peritoneal tumour microenvironment of high-grade serous ovarian cancer.
    Leinster DA; Kulbe H; Everitt G; Thompson R; Perretti M; Gavins FN; Cooper D; Gould D; Ennis DP; Lockley M; McNeish IA; Nourshargh S; Balkwill FR
    J Pathol; 2012 Jun; 227(2):136-45. PubMed ID: 22322968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated local immunity by CC chemokine ligand 19-transduced embryonic endothelial progenitor cells suppresses metastasis of murine ovarian cancer.
    Hamanishi J; Mandai M; Matsumura N; Baba T; Yamaguchi K; Fujii S; Konishi I
    Stem Cells; 2010 Jan; 28(1):164-73. PubMed ID: 19911426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo selection of highly metastatic human ovarian cancer sublines reveals role for AMIGO2 in intra-peritoneal metastatic regulation.
    Liu Y; Yang J; Shi Z; Tan X; Jin N; O'Brien C; Ott C; Grisoli A; Lee E; Volk K; Conroy M; Franz E; Bryant A; Campbell L; Crowley B; Grisoli S; Alexandrou AT; Li C; Harper EI; Asem M; Johnson J; Leonard A; Santanello K; Klein A; Wang Q; Zhang S; Hilliard TS; Stack MS
    Cancer Lett; 2021 Apr; 503():163-173. PubMed ID: 33524500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.